Role of MicroRNA in Heart Transplant

Nog, Rajat; Gupta, Chhaya; Panza, Julio A.

doi:10.1097/crd.0000000000000393

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs are single stranded RNAs molecules about 22 nucleotides in length that can regulate gene expression at the post-transcriptional level and play a critical role in cardiac fibrosis, mainly including left ventricular fibrosis, right ventricular fibrosis and atrial fibrosis (Table 1 , Ref. [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ]).…”

Section: Mirnas In Cardiac Fibrosismentioning

confidence: 99%

“…In addition, many ncRNAs can be used as noninvasive detection indicators, such as for the assessment of myocardial injury after HT. MiR-133b has been found to be an important marker of myocardial injury and to be associated with hemodynamic changes evident early after transplantation [ 34 ]. Circ-FSCN1 silencing produced tolerogenic dendritic cells, which prevented alloimmune rejection in HT, prolonged patient survival and reduced myocardial fibrosis [ 71 ].…”

Section: Ncrnas and Other Factors Associated With Cardiac Fibrosismentioning

confidence: 99%

See 1 more Smart Citation

Noncoding RNAs and Cardiac Fibrosis

Wu¹,

Bao²,

Li³

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Myocardial fibrosis is a common pathological feature of various terminal cardiovascular diseases. Progressive fibrosis is the pathological basis for the development and progression of many cardiac arrhythmias and heart failure. There are no effective reversal drugs for myocardial fibrosis due to the lack of understanding of the molecular mechanisms. Noncoding RNAs, a class of RNAs that do not function in coding proteins, have been found to be intimately involved in the life cycle of cardiomyocyte differentiation, transcription and apoptosis and are important regulators of cardiovascular disease. An increasing number of studies have shown that noncoding RNAs regulate the proliferation and transformation of cardiac fibroblasts through related signaling pathways and can be used as potential biomarkers and novel therapeutic targets for cardiac fibrosis. This article reviews the relationship between noncoding RNAs and cardiac fibrosis.

show abstract

Section: Mirnas In Cardiac Fibrosismentioning

confidence: 99%

Section: Ncrnas and Other Factors Associated With Cardiac Fibrosismentioning

confidence: 99%

Noncoding RNAs and Cardiac Fibrosis

Wu¹,

Bao²,

Li³

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…miRNAs are small, non‐coded, single‐stranded RNA sequences that regulate gene expression at a post‐transcriptional level. They circulate in stable forms in the blood and appear to play a role in endothelial homeostasis, making them a desirable biomarker for CAV 77‐79 . A cross‐sectional study, published in 2015, looked at endothelium enriched miRNAs and found they had the ability to discriminate between those with and without CAV and that certain miRNAs had greater diagnostic abilities than others 78 .…”

Section: Research and Future Directionsmentioning

confidence: 99%

“…biomarker for CAV. [77][78][79] A cross-sectional study, published in 2015, looked at endothelium enriched miRNAs and found they had the ability to discriminate between those with and without CAV and that certain miRNAs had greater diagnostic abilities than others. 78 Further studies continued to demonstrate specific miRNAs both in the serum and on endomyocardial biopsy as potential biomarkers for CAV.…”

Section: Biomarkersmentioning

confidence: 99%

Cardiac allograft vasculopathy: A review

Laks

Dipchand

2022

Pediatric Transplantation

View full text Add to dashboard Cite

Background Heart transplantation has become the standard of care for pediatric patients with end‐stage heart disease, and outcomes have consistently improved over the last few decades. CAV, however, remains a leading cause of morbidity and mortality in heart transplantation and is the leading cause of death beyond 3 years post‐transplantation. We sought out to provide an in‐depth overview of CAV in the pediatric heart transplant population. Methods Database searches were conducted in both Medline and Embase on the topic of cardiac vasculopathy in pediatric heart transplant recipients. The search used five broad concept terms: heart transplant; pediatric; CAV; diagnosis, prognosis, and risk factors; and guidelines and reviews. References were captured if there was at least one term in each of the concepts. The search was limited to articles in the English language. Results A total of 148 articles were identified via the literature search with further articles identified via review of references. Pediatric data regarding the etiology and development of CAV remain limited although knowledge about the immune and non‐immune factors playing a role are increasing. CAV continues to be difficult to detect with many invasive and non‐invasive methods available, yet their effectiveness in the detection of CAV remains suboptimal. There remains no proven medical intervention to treat or reverse established CAV disease, and CAV is associated with high rates of graft loss once detected. However, several medications are used in hopes of preventing, slowing progression, or modifying the outcomes. Conclusion This review provides a comprehensive overview of CAV, discusses its clinical presentation, risk factors, diagnostic tools used to identify CAV in the pediatric population, and highlights the current therapeutic options and the need for ongoing research.

show abstract

“…Aside from advances in imaging, there has been a concurrent search for biomarkers associated with CAV for early detection and as potential treatment targets. These include osteopontin, a pro-inflammatory cytokine that correlates with severe CAV [39]; endothelin-1, a vasoconstrictor peptide associated with accelerated CAV development [40]; and various microRNAs [41][42][43], among others [44][45][46][47][48]. These markers still require prospective validation to assess their utility in CAV detection, as well as continued evaluation as possible treatment targets.…”

Section: Cardiac Allograft Vasculopathy Detectionmentioning

confidence: 99%

Noninvasive methods to reduce cardiac complications postheart transplant

Zhou

Wolfson

Vaidya

2021

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewLong-term success of heart transplantation is limited by allograft rejection and cardiac allograft vasculopathy (CAV). Classic management has relied on frequent invasive testing to screen for early features of rejection and CAV to allow for early treatment. In this review, we discuss new developments in the screening and prevention of allograft rejection and CAV. Recent findingsNewer noninvasive screening techniques show excellent sensitivity and specificity for the detection of clinically significant rejection. New biomarkers and treatment targets continue to be identified and await further studies regarding their utility in preventing allograft vasculopathy. SummaryNoninvasive imaging and biomarker testing continue to show promise as alternatives to invasive testing for allograft rejection. Continued validation of their effectiveness may lead to new surveillance protocols with reduced frequency of invasive testing. Furthermore, these noninvasive methods will allow for more personalized strategies to reduce the complications of long-term immunosuppression whereas continuing the decline in the overall rate of allograft rejection.

show abstract

Role of MicroRNA in Heart Transplant

Cited by 5 publications

References 17 publications

Noncoding RNAs and Cardiac Fibrosis

Noncoding RNAs and Cardiac Fibrosis

Cardiac allograft vasculopathy: A review

Noninvasive methods to reduce cardiac complications postheart transplant

Contact Info

Product

Resources

About